novo nordisk new glp 1 Nordisk's Wegovy pill launch draws wave of patients to GLP-1s Novo Nordisk says US approves

In a clinical trial, participants who took oral Wegovy lost 13.6% of their total body weight on average over about 15 months, compared with a 2.2% loss if they took a placebo, or dummy pill

Some arent very stable, so they will lose effectiveness when exposed to light, heat, or air in general

The review also documents rapid gene expression changes in skin wounds that parallel healing observed in gastrointestinal tract, tendon, ligament, muscle, bone, nerve, and blood vessels

The peptide should be stored refrigerated to maintain stability and potency

doi: 10.1016/j.jad.2010.08.001

Linus Pauling Institute Oregon State University Updated in October 2018 by: Barbara Delage, Ph.D